In the China group:
The most common serious adverse reaction in the China group was the bone
marrow producing fewer blood cells than the body needed. The table below
shows the serious adverse reactions that happened in more than 1 participant
in at least 1 treatment group. There were other serious adverse reactions, but
these happened in fewer participants.
Most common serious adverse reactions in the China group
Durvalumab with Standard
tremelimumab treatment
(out of 77 (out of 78
Serious adverse reaction participants) participants)
Bone marrow producing fewer blood
cells than the body needed. Bone
none 3.8% (3)
marrow is the spongy tissue inside large
bones where blood cells are produced.
Low levels of red blood cells none 2.6% (2)
Rash 2.6% (2) none
Reduced levels of a type of white blood
none 2.6% (2)
cell called a neutrophil
Reduced levels of platelets, a type of
none 2.6% (2)
blood cell that can help form clots
There were 1.3% of participants who died because of serious adverse reactions.
This was 1 out of 77 participants. This participant got durvalumab together with
tremelimumab.
16 | Clinical Study Results